FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 275 filers reported holding FATE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.99 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $73,574,000 | +20.8% | 847,723 | +14.7% | 0.08% | +9.6% |
| Q1 2021 | $60,929,000 | +13.1% | 738,982 | +24.8% | 0.07% | +4.3% |
| Q4 2020 | $53,854,000 | +2.2% | 592,253 | -55.1% | 0.07% | -14.6% |
| Q3 2020 | $52,680,000 | +18.3% | 1,318,000 | +1.6% | 0.08% | +6.5% |
| Q2 2020 | $44,527,000 | +254.0% | 1,297,779 | +129.2% | 0.08% | +185.2% |
| Q1 2020 | $12,578,000 | -47.9% | 566,312 | -54.1% | 0.03% | -37.2% |
| Q4 2019 | $24,141,000 | -30.7% | 1,233,597 | -45.0% | 0.04% | +16.2% |
| Q3 2019 | $34,822,000 | +396.6% | 2,242,236 | +549.1% | 0.04% | +146.7% |
| Q2 2019 | $7,012,000 | – | 345,418 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |